Risk alert: FDA restricts sale of Essure Permanent Birth Control

April 9, 2018

The FDA has restricted the sale and distribution of the Essure Permanent Birth Control System to only physicians and health care facilities that agree to use the FDA-approved “Patient-Doctor Discussion Checklist — Acceptance of Risk and Informed Decision Acknowledgement.”

Health care professionals must review this checklist with patients and give them the opportunity to sign it before Essure implantation.    

This new safety measure has been enacted to ensure that women who receive Essure have been informed of the risks and benefits of the device. 

Learn more

 

Previous Presentation
Ransomware attacks
Ransomware attacks

The case studies in this presentation are real life examples of ransomware attacks on health care organizat...

Next Article
Law Requires Texas Physicians to Query PMP Before Prescribing Opioids
Law Requires Texas Physicians to Query PMP Before Prescribing Opioids

Texas physicians will soon be required to check the Texas Prescription Monitoring database before prescribi...